Business
Cytophage Reports Q2 Financials including Business Update for First Half of 2024
(TheNewswire) Winnipeg – TheNewswire - August 28, 2024. Cytophage Technologi...
About this update from Cytophage Technologies Ltd.
[{"type":"text","content":"Cytophage Reports Q2 Financials including Business Update for First Half of 2024\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Winnipeg –\n \n\n TheNewswire\n-\n \n\n August 28, 2024. Cytophage Technologies Ltd.\n(\n \n\n TSXV:CYTO\n \n\n ) (“\n \n\n Cytophage\n \n\n ” or the “Company”),\n \n\n\n the only publicly traded phage company\nthat is focused on bacteriophage solutions for both animal health and\nhuman health, today announced the filing of its financial results for\nthe second quarter (Q2) ended June 30, 2024. The financial statements\nand the accompanying\n \n\n\n Management\nDiscussion and Analysis are accessible under the Company’s profile\nat\n \n\n\n sedarplus.com\n \n\n\n .\n \n\n\n\n Q2 2024\n \n\n Business Highlights\n \n\n\n\n\n\n Cytophage moved into its new 20,000 sq ft RD and\nproduction facility that includes state-of-the-art labs and\nmanufacturing. A Grand Opening for the new global headquarters is\nexpected to take place in the fall. The Company anticipates that, once\nestablished, this will be one of the premier phage manufacturing\ncentres in North America capable of developing a wide variety of phage\ntherapies for both animal and human health sectors.\n \n\n\n\n\n\n Development and testing of lyophilized tablets advanced\nto a final stage in the second quarter. These freeze-dried/stabilized\ntablets represent a simplified application option for bacteriophages\nthat can treat multiple types of bacteria such as\n \n\n E. coli and Salmonella\n \n\n throughout the lifecycle of a chicken. Cytophage\n \n\n\n believes the lyophilized tablet solution\nis a unique and innovative product, offering increased flexibility,\nstability and application versatility that has the potential to\nradically transform phage delivery within the poultry\nindustry.\n \n\n\n\n\n\n\n\n Cytophage signed a Letter of Intent with a leading Pan-Asian\nindustrial agrifood company headquartered in Singapore. The LOI\noutlines a collaboration pathway between Cytophage and this company\nthat operates in six countries and derives approximately 80% of its\nmulti-billion-dollar revenue from poultry operations. Cytophage\nproducts could be used to\n \n\n\n\n improve\nproduction numbers by decreasing bacterial loads throughout the\nlifecycle of chickens.  Tr...